{"id":"cephalexin","rwe":[],"_fda":{"id":"fc0f8e56-f656-4ae6-9c83-c7bc4046b42f","set_id":"02b5cd6f-3df8-43c1-879d-217fcf55231a","openfda":{"unii":["OBN7UDS42Y"],"route":["ORAL"],"rxcui":["309114"],"spl_id":["fc0f8e56-f656-4ae6-9c83-c7bc4046b42f"],"brand_name":["Cephalexin"],"spl_set_id":["02b5cd6f-3df8-43c1-879d-217fcf55231a"],"package_ndc":["50090-0081-0","50090-0081-1"],"product_ndc":["50090-0081"],"generic_name":["CEPHALEXIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CEPHALEXIN"],"manufacturer_name":["A-S Medication Solutions"],"application_number":["ANDA065253"],"original_packager_product_ndc":["65862-019"]},"version":"16","pregnancy":["8.1 Pregnancy Risk Summary Available data from published epidemiologic studies and pharmacovigilance case reports over several decades with cephalosporin use, including cephalexin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) . Animal reproduction studies with mice and rats using oral doses of cephalexin that are 0.6- and 1.2-times the maximum recommended human dose (MRHD) based on body surface area during organogenesis revealed no evidence of harm to the fetus (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data While available studies cannot definitively establish the absence of risk, published data from epidemiologic studies and postmarketing case reports over several decades have not identified a consistent association with cephalosporin use, including cephalexin, during pregnancy, and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. Animal Data In animal reproduction studies, pregnant mice and rats administered oral cephalexin doses of 250 or 500 mg/kg/day (approximately 0.6 and 1.2 times the MRHD) based on body surface area, respectively during the period of organogenesis showed no adverse effects on embryofetal development. In a pre-and post-natal developmental toxicity study, pregnant rats that received oral doses of 250 or 500 mg/kg/day of cephalexin from Day 15 of pregnancy to litter Day 21 showed no adverse effects on parturition, litter size, or growth of offspring."],"overdosage":["10 OVERDOSAGE Symptoms of oral overdose may include nausea, vomiting, epigastric distress, diarrhea, and hematuria. In the event of an overdose, institute general supportive measures. Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of cephalexin."],"description":["11 DESCRIPTION Cephalexin capsules, USP is a semisynthetic cephalosporin antibacterial drug intended for oral administration. It is 7-(D-α-Amino-α-phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid monohydrate. Cephalexin has the molecular formula C 16 H 17 N 3 O 4 S•H 2 O and the molecular weight is 365.41. Cephalexin has the following structural formula: Each capsule contains cephalexin monohydrate equivalent to 250 mg or 500 mg of cephalexin. The capsules also contain the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, D&C Yellow No. 10, FD&C Blue No. 1, FD&C Yellow No. 6, gelatin, magnesium stearate, titanium dioxide, and sodium lauryl sulfate. FDA approved dissolution test specifications differs from the USP. structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Product: 50090-0081 NDC: 50090-0081-0 40 CAPSULE in a BOTTLE NDC: 50090-0081-1 28 CAPSULE in a BOTTLE"],"geriatric_use":["8.5 Geriatric Use Of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62%) were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. This drug is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection [see Warnings and Precautions (5.4) ]."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of cephalexin in pediatric patients was established in clinical trials for the dosages described in the dosage and administration section [see Dosage and Administration (2.2) ]."],"effective_time":"20250211","pharmacokinetics":["12.3 Pharmacokinetics Absorption: Cephalexin is acid stable and may be given without regard to meals. Following doses of 250 mg, 500 mg, and 1 g, average peak serum levels of approximately 9, 18, and 32 mcg/mL, respectively, were obtained at 1 hour. Serum levels were detectable 6 hours after administration (at a level of detection of 0.2 mcg/mL). Distribution: Cephalexin is approximately 10% to 15% bound to plasma proteins. Excretion: Cephalexin is excreted in the urine by glomerular filtration and tubular secretion. Studies showed that over 90% of the drug was excreted unchanged in the urine within 8 hours. During this period, peak urine concentrations following the 250 mg, 500 mg, and 1 g doses were approximately 1000, 2200, and 5000 mcg/mL respectively. Drug Interactions: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean C max and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious events are described in greater detail in the Warning and Precautions section: Hypersensitivity reactions [see Warning and Precautions (5.1) ] Clostridium difficile -associated diarrhea [see Warnings and Precautions (5.2) ] Direct Coombs’ Test Seroconversion [see Warnings and Precautions (5.3) ] Seizure Potential [see Warnings and Precautions (5.4) ] Effect on Prothrombin Activity [see Warnings and Precautions (5.5) ] Development of Drug-Resistant Bacteria [see Warnings and Precautions (5.6) ] The most common adverse reactions associated with cephalexin include diarrhea, nausea, vomiting, dyspepsia and abdominal pain . ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, the most frequent adverse reaction was diarrhea. Nausea and vomiting, dyspepsia, gastritis, and abdominal pain have also occurred. As with penicillins and other cephalosporins, transient hepatitis and cholestatic jaundice have been reported. Other reactions have included hypersensitivity reactions, genital and anal pruritus, genital candidiasis, vaginitis and vaginal discharge, dizziness, fatigue, headache, agitation, confusion, hallucinations, arthralgia, arthritis, and joint disorder. Reversible interstitial nephritis has been reported. Eosinophilia, neutropenia, thrombocytopenia, hemolytic anemia, and slight elevations in aspartate transaminase (AST) and alanine transaminase (ALT) have been reported. In addition to the adverse reactions listed above that have been observed in patients treated with cephalexin, the following adverse reactions and other altered laboratory tests have been reported for cephalosporin class antibacterial drugs: Other Adverse Reactions : Fever, colitis, aplastic anemia, hemorrhage, renal dysfunction, and toxic nephropathy. Altered Laboratory Tests : Prolonged prothrombin time, increased blood urea nitrogen (BUN), increased creatinine, elevated alkaline phosphatase, elevated bilirubin, elevated lactate dehydrogenase (LDH), pancytopenia, leukopenia, and agranulocytosis."],"contraindications":["4 CONTRAINDICATIONS Cephalexin capsules are contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. Patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Metformin: increased metformin concentrations. Monitor for hypoglycemia. ( 7.1 ) Probenecid-The renal excretion of cephalexin is inhibited by probenecid. Co-administration of probenecid with cephalexin is not recommended. ( 7.2 ) Administration of cephalexin may result in a false-positive reaction glucose in the urine. ( 7.3 ) 7.1 Metformin Administration of cephalexin with metformin results in increased plasma metformin concentrations and decreased renal clearance of metformin. Careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin [see Clinical Pharmacology (12.3) ]. 7.2 Probenecid The renal excretion of cephalexin is inhibited by probenecid. Co-administration of probenecid with cephalexin is not recommended. 7.3 Interaction with Laboratory or Diagnostic Testing A false-positive reaction may occur when testing for the presence of glucose in the urine using Benedict’s solution or Fehling’s solution."],"labor_and_delivery":["8.2 Lactation Risk Summary Data from a published clinical lactation study reports that cephalexin is present in human milk. The Relative Infant Dose (RID) is considered to be <1% of the maternal weight adjusted dose. There are no data on the effects of cephalexin on the breastfed child or on milk production. The development of health benefits of breastfeeding should be considered along with the mother’s clinical need for cephalexin and any potential adverse effects on the breastfed child from cephalexin or from the underlying maternal condition."],"mechanism_of_action":["12.1 Mechanism of Action Cephalexin is a cephalosporin antibacterial drug [see Microbiology (12.4) ] ."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Cephalexin is a cephalosporin antibacterial drug [see Microbiology (12.4) ] . 12.3 Pharmacokinetics Absorption: Cephalexin is acid stable and may be given without regard to meals. Following doses of 250 mg, 500 mg, and 1 g, average peak serum levels of approximately 9, 18, and 32 mcg/mL, respectively, were obtained at 1 hour. Serum levels were detectable 6 hours after administration (at a level of detection of 0.2 mcg/mL). Distribution: Cephalexin is approximately 10% to 15% bound to plasma proteins. Excretion: Cephalexin is excreted in the urine by glomerular filtration and tubular secretion. Studies showed that over 90% of the drug was excreted unchanged in the urine within 8 hours. During this period, peak urine concentrations following the 250 mg, 500 mg, and 1 g doses were approximately 1000, 2200, and 5000 mcg/mL respectively. Drug Interactions: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean C max and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug. 12.4 Microbiology Mechanism of Action Cephalexin is a bactericidal agent that acts by the inhibition of bacterial cell-wall synthesis. Resistance Methicillin-resistant staphylococci and most isolates of enterococci are resistant to cephalexin. Cephalexin is not active against most isolates of Enterobacter spp., Morganella morganii , and Proteus vulgaris . Cephalexin has no activity against Pseudomonas spp., or Acinetobacter calcoaceticus . Penicillin-resistant Streptococcus pneumoniae is usually cross-resistant to beta-lactam antibacterial drugs. Antimicrobial Activity Cephalexin has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections [ see Indications and Usage (1) ]. Gram-positive bacteria Staphylococcus aureus (methicillin-susceptible isolates only) Streptococcus pneumoniae (penicillin-susceptible isolates) Gram-negative bacteria Escherichia coli Haemophilus influenzae Klebsiella pneumoniae Moraxella catarrhalis Proteus mirabilis Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"indications_and_usage":["1 INDICATIONS AND USAGE Cephalexin capsules are a cephalosporin antibacterial drug indicated for the treatment of the following infections caused by susceptible isolates of designated bacteria: Respiratory tract infection ( 1.1 ) Otitis media ( 1.2 ) Skin and skin structure infections ( 1.3 ) Bone infections ( 1.4 ) Genitourinary tract infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Respiratory Tract Infections Cephalexin capsules are indicated for the treatment of respiratory tract infections caused by susceptible isolates of Streptococcus pneumoniae and Streptococcus pyogenes. 1.2 Otitis Media Cephalexin capsules are indicated for the treatment of otitis media caused by susceptible isolates of Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis. 1.3 Skin and Skin Structure Infections Cephalexin capsules are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus and Streptococcus pyogenes . 1.4 Bone Infections Cephalexin capsules are indicated for the treatment of bone infections caused by susceptible isolates of Staphylococcus aureus and Proteus mirabilis. 1.5 Genitourinary Tract Infections Cephalexin capsules are indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae . 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information is available, this information should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Serious hypersensitivity (anaphylactic) reactions : Prior to use, inquire regarding history of hypersensitivity to beta-lactam antibacterial drugs. Discontinue the drug if signs or symptoms of an allergic reaction occur and institute supportive measures. ( 5.1 ) Clostridium difficile -associated diarrhea (CDAD ): Evaluate if diarrhea occurs. ( 5.2 ) Direct Coombs’ Test Seroconversion : If anemia develops during or after cephalexin therapy, evaluate for drug-induced hemolytic anemia. ( 5.3 ) Seizure Potential : Use lower dose in patients with renal impairment. ( 5.4 ) 5.1 Hypersensitivity Reactions Allergic reactions in the form of rash, urticaria, angioedema, anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis have been reported with the use of cephalexin. Before therapy with cephalexin is instituted, inquire whether the patient has a history of hypersensitivity reactions to cephalexin, cephalosporins, penicillins, or other drugs. Cross-hypersensitivity among beta-lactam antibacterial drugs may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to cephalexin occurs, discontinue the drug and institute appropriate treatment. 5.2 Clostridium difficile -Associated Diarrhea Clostridium difficile - associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cephalexin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. 5.3 Direct Coombs’ Test Seroconversion Positive direct Coombs’ tests have been reported during treatment with the cephalosporin antibacterial drugs including cephalexin. Acute intravascular hemolysis induced by cephalexin therapy has been reported. If anemia develops during or after cephalexin therapy, perform a diagnostic work-up for drug-induced hemolytic anemia, discontinue cephalexin and institute appropriate therapy. 5.4 Seizure Potential Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures occur, discontinue cephalexin. Anticonvulsant therapy can be given if clinically indicated. 5.5 Prolonged Prothrombin Time Cephalosporins may be associated with prolonged prothrombin time. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antibacterial therapy, and patients receiving anticoagulant therapy. Monitor prothrombin time in patients at risk and manage as indicated. 5.6 Development of Drug-Resistant Bacteria Prescribing cephalexin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Prolonged use of cephalexin may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Lifetime studies in animals have not been performed to evaluate the carcinogenic potential of cephalexin. Tests to determine the mutagenic potential of cephalexin have not been performed. In male and female rats, fertility and reproductive performance were not affected by cephalexin oral doses up to 1.5 times the highest recommended human dose based upon body surface area."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Allergic Reactions Advise patients that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment. Ask the patient about any previous hypersensitivity reactions to cephalexin, other beta-lactams (including cephalosporins) or other allergens (5.1) Diarrhea Advise patients that diarrhea is a common problem caused by antibacterial drugs and usually resolves when the drug is discontinued. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, advise patients to contact their healthcare provider. Antibacterial Resistance Counsel patients that antibacterial drugs including cephalexin, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cephalexin is prescribed to treat a bacterial infection, tell patients that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cephalexin or other antibacterial drugs in the future. Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India Revised: 12/2024"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Adults and patients at least 15 years of age The usual dose is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered ( 2.1 ) Pediatric patients (over 1 year of age) Otitis media: 75 to 100 mg/kg in equally divided doses every 6 hours ( 2.2 ) All other indications: 25 to 50 mg/kg given in equally divided doses ( 2.2 ) In severe infections: 50 to 100 mg/kg may be administered in equally divided doses ( 2.2 ) Duration of therapy ranges from 7 to 14 days depending on the infection type and severity. ( 2 ) Dosage adjustment is required in patients with severe and end stage renal disease (ESRD) defined as creatinine clearance below 30 mL/min. ( 2.3 ) 2.1 Adults and Pediatric Patients at Least 15 Years of Age The usual dose of oral cephalexin capsules is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered. Treatment is administered for 7 to 14 days. For more severe infections larger doses of oral cephalexin capsules may be needed, up to 4 grams daily in two to four equally divided doses. 2.2 Pediatric Patients (over 1 year of age) The recommended total daily dose of oral cephalexin capsules for pediatric patients is 25 to 50 mg/kg given in equally divided doses for 7 to 14 days. In the treatment of β-hemolytic streptococcal infections, duration of at least 10 days is recommended. In severe infections, a total daily dose of 50 to 100 mg/kg may be administered in equally divided doses. For the treatment of otitis media, the recommended daily dose is 75 to 100 mg/kg given in equally divided doses. 2.3 Dosage Adjustments in Adult and Pediatric Patients at Least 15 Years of Age with Renal Impairment Administer the following dosing regimens for cephalexin capsules to patients with renal impairment [see Warnings and Precautions (5.4) and Use in Specific Populations (8.6) ] . Table 1. Recommended Dose Regimen for Patients with Renal Impairment *There is insufficient information to make dose adjustment recommendations in patients on hemodialysis. Renal function Dose regimen recommendation Creatinine clearance > 60 mL/min No dose adjustment Creatinine clearance 30 to 59 mL/min No dose adjustment; maximum daily dose should not exceed 1g Creatinine clearance 15 to 29 mL/min 250 mg, every 8 hours or every 12 hours Creatinine clearance 5 to 14 mL/min not yet on dialysis* 250 mg, every 24 hours Creatinine clearance 1 to 4 mL/min not yet on dialysis* 250 mg, every 48 hours or every 60 hours"],"spl_product_data_elements":["Cephalexin Cephalexin CEPHALEXIN CEPHALEXIN ANHYDROUS MICROCRYSTALLINE CELLULOSE CROSCARMELLOSE SODIUM YELLOW 10 BLUE 1 FD&C YELLOW NO. 6 GELATIN MAGNESIUM STEARATE CI 77891 SODIUM LAURYL SULFATE Dark Green Opaque, Light Green Opaque A;43;500;mg"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS 250 mg capsules : Dark green opaque/white size “2” hard gelatin capsule filled with off white granular powder and imprinted with “A 42” on dark green opaque cap and “250 mg” on white body with black ink. 500 mg capsules : Dark green opaque/light green opaque size “0” hard gelatin capsule filled with off white granular powder and imprinted with “A 43” on dark green opaque cap and “500 mg” on light green opaque body with black ink. Capsules: 250 mg and 500 mg ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Renal Impairment: Monitor patients longer for toxicity and drug interactions due to delayed clearance. (8.6) 8.1 Pregnancy Risk Summary Available data from published epidemiologic studies and pharmacovigilance case reports over several decades with cephalosporin use, including cephalexin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) . Animal reproduction studies with mice and rats using oral doses of cephalexin that are 0.6- and 1.2-times the maximum recommended human dose (MRHD) based on body surface area during organogenesis revealed no evidence of harm to the fetus (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data While available studies cannot definitively establish the absence of risk, published data from epidemiologic studies and postmarketing case reports over several decades have not identified a consistent association with cephalosporin use, including cephalexin, during pregnancy, and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. Animal Data In animal reproduction studies, pregnant mice and rats administered oral cephalexin doses of 250 or 500 mg/kg/day (approximately 0.6 and 1.2 times the MRHD) based on body surface area, respectively during the period of organogenesis showed no adverse effects on embryofetal development. In a pre-and post-natal developmental toxicity study, pregnant rats that received oral doses of 250 or 500 mg/kg/day of cephalexin from Day 15 of pregnancy to litter Day 21 showed no adverse effects on parturition, litter size, or growth of offspring. 8.2 Lactation Risk Summary Data from a published clinical lactation study reports that cephalexin is present in human milk. The Relative Infant Dose (RID) is considered to be <1% of the maternal weight adjusted dose. There are no data on the effects of cephalexin on the breastfed child or on milk production. The development of health benefits of breastfeeding should be considered along with the mother’s clinical need for cephalexin and any potential adverse effects on the breastfed child from cephalexin or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of cephalexin in pediatric patients was established in clinical trials for the dosages described in the dosage and administration section [see Dosage and Administration (2.2) ]. 8.5 Geriatric Use Of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62%) were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. This drug is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection [see Warnings and Precautions (5.4) ]. 8.6 Renal Impairment Cephalexin should be administered with careful monitoring in the presence of renal impairment (creatinine clearance < 30 mL/min, with or without dialysis). Under such conditions, careful clinical observation and laboratory studies renal function monitoring should be conducted because safe dosage may be lower than that usually recommended [see Dosage and Administration (2.3) ] . Monitor patients longer for toxicity and drug interactions due to delayed clearance."],"dosage_and_administration_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"50%\"/><col width=\"50%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Adults and patients at least 15 years of age </td><td styleCode=\"Rrule\" valign=\"top\">The usual dose is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered (<linkHtml href=\"#Section_2.1\">2.1</linkHtml>) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">Pediatric  patients (over 1 year of age) </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Otitis media: 75 to 100 mg/kg in equally divided doses every 6 hours (<linkHtml href=\"#Section_2.2\">2.2</linkHtml>)</item><item>All other indications: 25 to 50 mg/kg given in equally divided doses (<linkHtml href=\"#Section_2.2\">2.2</linkHtml>)</item><item>In severe infections: 50 to 100 mg/kg may be administered in equally divided doses (<linkHtml href=\"#Section_2.2\">2.2</linkHtml>)</item></list></td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 1. Recommended Dose Regimen for Patients with Renal Impairment</caption><colgroup><col width=\"46.72%\"/><col width=\"53.28%\"/></colgroup><tfoot><tr><td colspan=\"2\">*There is insufficient information to make dose adjustment recommendations in patients on hemodialysis.<content styleCode=\"bold\"/></td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"><content styleCode=\"bold\">Renal function </content> </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"middle\"><content styleCode=\"bold\">Dose regimen recommendation </content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Creatinine clearance &gt; 60 mL/min  </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"middle\">No dose adjustment  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Creatinine clearance 30 to 59 mL/min  </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"middle\">No dose adjustment; maximum daily dose should not exceed 1g  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Creatinine clearance 15 to 29 mL/min  </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"middle\">250 mg, every 8 hours or every 12 hours  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Creatinine clearance 5 to 14 mL/min not yet on dialysis*  </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"middle\">250 mg, every 24 hours  </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Creatinine clearance 1 to 4 mL/min not yet on dialysis*  </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"middle\">250 mg, every 48 hours or every 60 hours  </td></tr></tbody></table>"],"package_label_principal_display_panel":["Cephalexin Label Image"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Lifetime studies in animals have not been performed to evaluate the carcinogenic potential of cephalexin. Tests to determine the mutagenic potential of cephalexin have not been performed. In male and female rats, fertility and reproductive performance were not affected by cephalexin oral doses up to 1.5 times the highest recommended human dose based upon body surface area."]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"CHRONIC KIDNEY DISEASE","source":"FDA FAERS","actionTaken":"2155 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"1554 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"1538 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"1364 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1351 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1240 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1221 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1165 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"1132 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"1092 reports"}],"drugInteractions":[{"drug":"Metformin","severity":"major","mechanism":"Increased plasma metformin concentrations and decreased renal clearance of metformin","management":"Careful patient monitoring and dose adjustment of metformin is recommended","clinicalEffect":"Increased risk of hypoglycemia"},{"drug":"Probenecid","severity":"major","mechanism":"Inhibition of renal excretion of cephalexin","management":"Co-administration of probenecid with cephalexin is not recommended","clinicalEffect":"Increased cephalexin levels"},{"drug":"Laboratory or Diagnostic Testing","severity":"minor","mechanism":"False-positive reaction for glucose in the urine","management":"Consider alternative methods for glucose testing if necessary","clinicalEffect":"Potential misdiagnosis of glycosuria"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"Not specified","severity":"mild"},{"effect":"Nausea","drugRate":"Not specified","severity":"mild"},{"effect":"Vomiting","drugRate":"Not specified","severity":"mild"},{"effect":"Dyspepsia","drugRate":"Not specified","severity":"mild"},{"effect":"Abdominal pain","drugRate":"Not specified","severity":"mild"},{"effect":"Genital candidiasis","drugRate":"Not specified","severity":"mild"},{"effect":"Vaginitis","drugRate":"Not specified","severity":"mild"},{"effect":"Vaginal discharge","drugRate":"Not specified","severity":"mild"},{"effect":"Dizziness","drugRate":"Not specified","severity":"mild"},{"effect":"Fatigue","drugRate":"Not specified","severity":"mild"},{"effect":"Headache","drugRate":"Not specified","severity":"mild"},{"effect":"Agitation","drugRate":"Not specified","severity":"mild"},{"effect":"Confusion","drugRate":"Not specified","severity":"mild"},{"effect":"Hallucinations","drugRate":"Not specified","severity":"mild"}],"contraindications":["Cephalexin capsules are contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs."],"specialPopulations":{"Pregnancy":"Available data from published epidemiologic studies and pharmacovigilance case reports over several decades have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes.","Geriatric use":"No overall differences in safety or effectiveness were observed between elderly and younger subjects. However, elderly patients are more likely to have decreased renal function, so care should be taken in dose selection.","Paediatric use":"The safety and effectiveness of cephalexin in pediatric patients have been established in clinical trials for the dosages described in the dosage and administration section.","Renal impairment":"Monitor patients longer for toxicity and drug interactions due to delayed clearance. Dosage adjustment is required in patients with severe and end-stage renal disease (ESRD) defined as creatinine clearance below 30 mL/min.","Hepatic impairment":""},"seriousAdverseEvents":[{"event":"Hypersensitivity reactions","detail":"","severity":"serious","incidence":"Not specified"},{"event":"Clostridium difficile-associated diarrhea","detail":"","severity":"serious","incidence":"Not specified"},{"event":"Direct Coombs’ Test seroconversion","detail":"","severity":"serious","incidence":"Not specified"},{"event":"Seizure potential","detail":"","severity":"serious","incidence":"Not specified"},{"event":"Effect on prothrombin activity","detail":"","severity":"serious","incidence":"Not specified"},{"event":"Development of drug-resistant bacteria","detail":"","severity":"serious","incidence":"Not specified"}]},"trials":[],"_chembl":null,"aliases":["cefalexin"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0769/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$28","description":"CEPHALEXIN 125 MG/5 ML SUSP","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CEPHALEXIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:16:23.890378+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:16:29.257158+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:16:23.007906+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEPHALEXIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:16:29.586191+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:16:22.043566+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:17:28.732822+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:16:22.043595+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:16:31.107567+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Cephalexin is a cephalosporin antibacterial drug [see Microbiology (12.4) ] .","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:16:36.244580+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial penicillin-binding protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:30.642051+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:16:55.153071+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200366/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:30.286374+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following serious events are described in greater detail in the Warning and Precautions section: Hypersensitivity reactions [see Warning and Precautions (5.1) ] Clostridium difficile -associated diarrhea [see Warnings and Precautions (5.2) ] Direct Coombs’ Test Seroconversion [see Warnings and Precautions (5.3) ] Seizure Potential [see Warnings and Precautions (5.4) ] Effect on Prothrombin Activity [see Warnings and Precautions (5.5) ] Development of Drug-Resistant Bacter","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:16:38.730233+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:16:42.083318+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA065253","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:16:22.043598+00:00"}},"allNames":"CEPHALEXIN, cefalexin, cephalexin","offLabel":[],"timeline":[{"date":"","type":"neutral","milestone":"Discovery/IND filing","regulator":"none","description":"Exact date unknown"},{"date":"","type":"neutral","milestone":"Phase 1 initiation","regulator":"none","description":"Exact date unknown"},{"date":"","type":"neutral","milestone":"Phase 2 initiation","regulator":"none","description":"Exact date unknown"},{"date":"","type":"neutral","milestone":"Phase 3 initiation","regulator":"none","description":"Exact date unknown"},{"date":"","type":"positive","milestone":"FDA approval for respiratory tract infections","regulator":"FDA","description":"Exact date unknown"},{"date":"","type":"positive","milestone":"FDA approval for otitis media","regulator":"FDA","description":"Exact date unknown"},{"date":"","type":"positive","milestone":"FDA approval for skin and skin structure infections","regulator":"FDA","description":"Exact date unknown"},{"date":"","type":"positive","milestone":"FDA approval for bone infections","regulator":"FDA","description":"Exact date unknown"},{"date":"","type":"positive","milestone":"FDA approval for genitourinary tract infections","regulator":"FDA","description":"Exact date unknown"},{"date":"","type":"positive","milestone":"Label expansion for additional indications","regulator":"FDA","description":"Exact date unknown"},{"date":"","type":"negative","milestone":"Patent expiry","regulator":"none","description":"Exact date unknown"},{"date":"","type":"negative","milestone":"Generic competition begins","regulator":"none","description":"Exact date unknown"}],"_dailymed":{"setId":"52d8a080-eafc-46fe-82d9-6b69c6a3a38a","title":"CEPHALEXIN CAPSULE [PREFERRED PHARMACEUTICALS INC.]"},"aiSummary":"Cephalexin, a first-generation cephalosporin antibiotic, is marketed by various companies and is indicated for treating a range of bacterial infections. It works by inhibiting bacterial cell wall synthesis. Key approved indications include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. Cephalexin is differentiated by its broad-spectrum activity and oral administration, making it a convenient option for outpatient treatment. Despite being a generic drug, it remains significant in primary care settings due to its efficacy and safety profile.","ecosystem":[],"mechanism":{"target":"Penicillin-binding proteins (PBPs)","novelty":"generic","modality":"small molecule","drugClass":"First-generation cephalosporin","explanation":"Cephalexin is a first-generation cephalosporin that works by inhibiting the synthesis of the bacterial cell wall. It does this by binding to penicillin-binding proteins (PBPs), which are enzymes responsible for cross-linking peptidoglycan chains in the cell wall. By blocking these enzymes, cephalexin weakens the bacterial cell wall, leading to cell lysis and death. This mechanism makes cephalexin effective against a wide range of Gram-positive and some Gram-negative bacteria.","oneSentence":"Cephalexin is a cephalosporin antibacterial drug.","technicalDetail":"Cephalexin binds to PBPs, particularly PBP2, with high affinity, leading to the inhibition of peptidoglycan cross-linking. It has a broad spectrum of activity, including against Streptococcus pneumoniae, Staphylococcus aureus, and Haemophilus influenzae. Cephalexin is well-absorbed orally and has a half-life of approximately 1 hour.","_target_confidence":0.5},"_scrapedAt":"2026-03-27T23:31:58.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"notes":"","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"yes"},"references":[],"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T00:17:28.856449+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"name":"Amoxicillin","slug":"amoxicillin","company":"Various","advantage":"Broad-spectrum antibiotic, often used as a first-line treatment for many infections"},{"name":"Clindamycin","slug":"clindamycin","company":"Various","advantage":"Effective against anaerobic bacteria and some Gram-positive bacteria"},{"name":"Doxycycline","slug":"doxycycline","company":"Various","advantage":"Broad-spectrum antibiotic, effective against both Gram-positive and Gram-negative bacteria"},{"name":"Trimethoprim-sulfamethoxazole","slug":"trimethoprim-sulfamethoxazole","company":"Various","advantage":"Effective against a wide range of bacteria, including some resistant strains"},{"name":"Fluoroquinolones","slug":"fluoroquinolones","company":"Various","advantage":"Broad-spectrum activity, effective against both Gram-positive and Gram-negative bacteria"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"id":"cephalexin-respiratory-tract-infections","name":"Respiratory tract infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with respiratory tract infections caused by susceptible isolates of designated bacteria","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with respiratory tract infections caused by susceptible isolates of designated bacteria","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cephalexin-otitis-media","name":"Otitis media","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with otitis media caused by susceptible isolates of designated bacteria","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with otitis media caused by susceptible isolates of designated bacteria","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cephalexin-skin-and-skin-structure-infect","name":"Skin and skin structure infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with skin and skin structure infections caused by susceptible isolates of designated bacteria","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with skin and skin structure infections caused by susceptible isolates of designated bacteria","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cephalexin-bone-infections","name":"Bone infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with bone infections caused by susceptible isolates of designated bacteria","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with bone infections caused by susceptible isolates of designated bacteria","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cephalexin-genitourinary-tract-infections","name":"Genitourinary tract infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of designated bacteria","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of designated bacteria","diagnosticRequired":null,"brandNameForIndication":""}],"offLabel":[{"name":"Atopic dermatitis","notes":"Used in combination with other treatments to manage bacterial superinfections.","evidenceLevel":"moderate"}],"pipeline":[{"name":"Chronic urinary tract infection","notes":"","phase":"Phase 2","status":"NOT_YET_RECRUITING"},{"name":"Tuberculosis","notes":"","phase":"Phase 2","status":"UNKNOWN"},{"name":"Acute uncomplicated cystitis","notes":"","phase":"Phase 2","status":"UNKNOWN"}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07300670","phase":"PHASE1","title":"The Effect of Losartan on Cephalexin","status":"RECRUITING","sponsor":"Aleksi Tornio","startDate":"2026-03-04","conditions":"Possible Interaction Between Losartan and Cephalexin, Healthy","enrollment":12},{"nctId":"NCT04580472","phase":"PHASE4","title":"Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carilion Clinic","startDate":"2020-10-01","conditions":"Surgical Site Infection","enrollment":574},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":"Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity","enrollment":300},{"nctId":"NCT05020574","phase":"PHASE2","title":"Microbiome and Association With Implant Infections","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-09-28","conditions":"Breast Cancer, Breast Cancer Female, Genetic Predisposition to Disease","enrollment":200},{"nctId":"NCT01631617","phase":"PHASE2","title":"Effects of Treatments on Atopic Dermatitis","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2012-09-18","conditions":"Eczema, Dermatitis, Skin Diseases, Genetic","enrollment":130},{"nctId":"NCT06080698","phase":"NA","title":"Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-02-22","conditions":"Gram-negative Bacteremia","enrollment":1030},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT07202949","phase":"PHASE2","title":"A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2026-02-28","conditions":"Chronic Urinary Tract Infection","enrollment":192},{"nctId":"NCT05274672","phase":"PHASE4","title":"Role of Prophylactic Postoperative Antibiotics in HoLEP","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2023-03-01","conditions":"Benign Prostatic Hyperplasia, Urinary Tract Infections","enrollment":""},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":"Gram-negative Bacteremia","enrollment":2500},{"nctId":"NCT04876131","phase":"PHASE4","title":"Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-30","conditions":"Complicated Urinary Tract Infection, Infection, Pediatric Infectious Disease","enrollment":452},{"nctId":"NCT04538053","phase":"PHASE4","title":"BonE and Joint Infections - Simplifying Treatment in Children Trial","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-06-01","conditions":"Bone Infection, Septic Arthritis, Bone and Joint Infection","enrollment":285},{"nctId":"NCT06055712","phase":"PHASE4","title":"Antibiotic Prophylaxis in Pediatric Open Fractures","status":"ENROLLING_BY_INVITATION","sponsor":"St. Louis University","startDate":"2023-09-11","conditions":"Fractures, Open, Infections","enrollment":800},{"nctId":"NCT05852262","phase":"PHASE4","title":"High-dose Cephalexin for Cellulitis (HI-DOCC)","status":"ENROLLING_BY_INVITATION","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-08-30","conditions":"Cellulitis","enrollment":446},{"nctId":"NCT06127160","phase":"PHASE4","title":"Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis","status":"COMPLETED","sponsor":"Brett A Faine","startDate":"2024-06-04","conditions":"Pyelonephritis Acute","enrollment":35},{"nctId":"NCT05726318","phase":"PHASE4","title":"Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women","status":"COMPLETED","sponsor":"Megan Bradley","startDate":"2023-02-17","conditions":"UTI","enrollment":70},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":100},{"nctId":"NCT04297592","phase":"PHASE4","title":"Antibiotic Prophylaxis in High-Risk Arthroplasty Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2020-06-11","conditions":"Infections Joint Prosthetic, Overweight or Obesity, MSSA Colonization","enrollment":4618},{"nctId":"NCT07032883","phase":"NA","title":"Benson Relaxation Technique Effectiveness on Pain and Quality of Life Post Reconstructive Mammoplasty","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-06-25","conditions":"Breast Cancer","enrollment":68},{"nctId":"NCT06166667","phase":"NA","title":"Effect of Fecal Capsule on Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Shanxi Provincial People's Hospital","startDate":"2023-03-01","conditions":"Renal Insufficiency, Chronic","enrollment":20},{"nctId":"NCT01912651","phase":"PHASE4","title":"The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2013-07","conditions":"Facial Defect","enrollment":300},{"nctId":"NCT02829060","phase":"NA","title":"Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-01","conditions":"Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis","enrollment":330},{"nctId":"NCT04471246","phase":"PHASE4","title":"High-dose vs. Standard-dose Cephalexin for Cellulitis","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-08-16","conditions":"Cellulitis","enrollment":69},{"nctId":"NCT00560651","phase":"","title":"German Corneal Cross Linking Register","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suphi Taneri","startDate":"2007-11","conditions":"Keratoconus","enrollment":7500},{"nctId":"NCT04194216","phase":"PHASE3","title":"Antibiotic Prophylaxis in Rhinoplasty","status":"ENROLLING_BY_INVITATION","sponsor":"Stanford University","startDate":"2020-05-20","conditions":"Nasal Obstruction, Nasal Surgical Procedures","enrollment":864},{"nctId":"NCT02014558","phase":"PHASE1, PHASE2","title":"Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-10-09","conditions":"Acute Myeloid Leukemia","enrollment":265},{"nctId":"NCT06207786","phase":"NA","title":"Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2024-09-01","conditions":"Skin Cancer, Skin Cancer Face, Malignant Cutaneous Adnexal Neoplasm","enrollment":""},{"nctId":"NCT05925309","phase":"NA","title":"Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2023-07-01","conditions":"Biliary Atresia, Cholangitis, Anti-Bacterial Agents","enrollment":356},{"nctId":"NCT05893147","phase":"NA","title":"BALANCE+ Vanguard Phase","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-08-26","conditions":"Gram-negative Bacteremia","enrollment":174},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-30","conditions":"Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections","enrollment":199},{"nctId":"NCT00835081","phase":"PHASE1","title":"Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-09","conditions":"Healthy","enrollment":26},{"nctId":"NCT00834275","phase":"PHASE1","title":"Cefadroxil 500 mg Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-09","conditions":"Healthy","enrollment":26},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":"Staphylococcus Aureus Bacteremia","enrollment":290},{"nctId":"NCT04631185","phase":"NA","title":"Surgical Site Infection and Antibiotic Use Study","status":"COMPLETED","sponsor":"The Plastic Surgery Foundation","startDate":"2021-05-07","conditions":"Surgical Site Infection, Breast Reconstruction, Antibiotic Use","enrollment":235},{"nctId":"NCT05519072","phase":"PHASE4","title":"Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA","status":"RECRUITING","sponsor":"Atlantic Health System","startDate":"2022-08-16","conditions":"Antibiotic Prophylaxis","enrollment":140},{"nctId":"NCT06255652","phase":"","title":"Oral Versus Intravenous Antibiotic Prophylaxis Before Obstetric and Gynecological Procedures","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-10-01","conditions":"Site Infection","enrollment":1},{"nctId":"NCT05719285","phase":"PHASE4","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2022-12-06","conditions":"Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence","enrollment":100},{"nctId":"NCT04916951","phase":"PHASE1","title":"Oral Amoxicillin and Cephalexin PK/PD in Neonates","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2021-07-14","conditions":"Neonatal Infection","enrollment":60},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT04409093","phase":"NA","title":"Eponychial Stent Study","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-06-01","conditions":"Eponychial Stent, Nail Bed Injury","enrollment":54},{"nctId":"NCT03187106","phase":"PHASE1","title":"Prophylactic Antibiotics After Cesarean","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-08-01","conditions":"Surgical Site Infection","enrollment":321},{"nctId":"NCT05664568","phase":"PHASE2","title":"The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis","status":"UNKNOWN","sponsor":"Western Sydney Local Health District","startDate":"2023-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":30},{"nctId":"NCT05702762","phase":"PHASE2","title":"Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting","status":"UNKNOWN","sponsor":"Mercy Health Ohio","startDate":"2022-10-01","conditions":"Urinary Tract Infections","enrollment":160},{"nctId":"NCT03877289","phase":"PHASE4","title":"Efficacy of Oxybutynin in Paediatric Cystitis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-10","conditions":"Cystitis","enrollment":81},{"nctId":"NCT04834310","phase":"PHASE4","title":"Postoperative Antibiotics Following Primary and Secondary Breast Augmentation","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2021-04-01","conditions":"Surgical Site Infection, Capsular Contracture Associated With Breast Implant, Antibiotic Resistant Infection","enrollment":""},{"nctId":"NCT02375295","phase":"PHASE4","title":"Struvite Stones Antibiotic Study","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-03","conditions":"Kidney Stones","enrollment":28},{"nctId":"NCT02809131","phase":"PHASE3","title":"Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-04-01","conditions":"Sick Sinus Syndrome, Complete Heart Block, Syncope","enrollment":1010},{"nctId":"NCT03357419","phase":"NA","title":"The Effect of Prophylactic Antibiotics on Surgical Site Infection Lower Limb Skin Excisions","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2021-03","conditions":"Skin Lesion","enrollment":""},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":"Acute Infection","enrollment":589},{"nctId":"NCT04553419","phase":"PHASE3","title":"Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2020-07-27","conditions":"Cystic Fibrosis","enrollment":86},{"nctId":"NCT03802552","phase":"PHASE1","title":"Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-05-01","conditions":"Osteomyelitis, Septic Arthritis, Pyomyositis","enrollment":17},{"nctId":"NCT02512198","phase":"NA","title":"Electronic Prescription Data to Improve Primary Care Prescribing","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2015-07","conditions":"Physician's Practice Patterns","enrollment":236},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04723940","phase":"PHASE3","title":"Or v IV Antibiotics for Infection","status":"UNKNOWN","sponsor":"Rothman Institute Orthopaedics","startDate":"2021-01-25","conditions":"Joint Infection","enrollment":308},{"nctId":"NCT04285320","phase":"PHASE4","title":"Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections","status":"UNKNOWN","sponsor":"Atlantic Health System","startDate":"2021-03","conditions":"Recurrent Urinary Tract Infection","enrollment":100},{"nctId":"NCT04413019","phase":"","title":"Domiciliary Versus Hospital Management of PPROM","status":"COMPLETED","sponsor":"Ahmed Mohammed Selim","startDate":"2019-04-15","conditions":"Preterm Premature Rupture of Membrane","enrollment":3662},{"nctId":"NCT04577846","phase":"PHASE3","title":"SSI Rates in Patients Undergoing Mastectomy Without Reconstruction- A Multicenter, Double-blinded RCT.","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-11-01","conditions":"Surgical Site Infection","enrollment":384},{"nctId":"NCT01595529","phase":"PHASE2","title":"The SCOUT Study: \"Short Course Therapy for Urinary Tract Infections in Children\"","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05-18","conditions":"Urinary Tract Infection","enrollment":717},{"nctId":"NCT01507974","phase":"NA","title":"Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-01-16","conditions":"Pregnancy Complications","enrollment":220},{"nctId":"NCT03275623","phase":"PHASE4","title":"Management of Sub-Clinical Bacteriuria in Pregnancy","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-09-15","conditions":"Cystitis, Cystitis;Puerperium, Pyelonephritis","enrollment":60},{"nctId":"NCT02381470","phase":"PHASE2","title":"Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2019-02-11","conditions":"Pulmonary Tuberculosis","enrollment":58},{"nctId":"NCT01899781","phase":"PHASE4","title":"Prophylactic Antibiotic Treatment for Hand Lacerations Involving Flexor and/or Extensor Tendon","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2013-08","conditions":"Hand Laceration, Tendon Involved, Clean Laceration","enrollment":24},{"nctId":"NCT04146883","phase":"NA","title":"Post-procedure Antibiotic Prophylaxis for Cardiac Electrical Device Implantation: ABxFREE Study","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2019-08-20","conditions":"Post Procedural Infection, Pacemaker Electrode Infection, Antibiotics","enrollment":800},{"nctId":"NCT02276482","phase":"PHASE3","title":"Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-03-25","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial","enrollment":120},{"nctId":"NCT02297815","phase":"","title":"Comparative Effectiveness of Antibiotics for Respiratory Infections","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2014-01","conditions":"Acute Otitis Media, Acute Sinusitis, Group A Streptococcal Pharyngitis","enrollment":2472},{"nctId":"NCT01628666","phase":"PHASE4","title":"Prevention of Arrhythmia Device Infection Trial (PADIT)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2012-12","conditions":"Arrhythmia","enrollment":12814},{"nctId":"NCT00957827","phase":"NA","title":"Prophylactic Use of Antibiotics for Through and Through Lacerations of the Lip","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2009-08","conditions":"Through-and-through Lip Lacerations","enrollment":4},{"nctId":"NCT01500382","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-27","conditions":"Overactive Bladder, Overactive Urinary Bladder","enrollment":4},{"nctId":"NCT03736187","phase":"NA","title":"Antibiotics for Prevention of SSI in Obese Women Undergoing CS","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-04","conditions":"Surgical Site Infection","enrollment":280},{"nctId":"NCT01029782","phase":"PHASE2","title":"Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis","status":"COMPLETED","sponsor":"Kelowna General Hospital","startDate":"2010-05","conditions":"Cellulitis","enrollment":206},{"nctId":"NCT03569969","phase":"NA","title":"Comparison Tympanoplasty With Membrane Amniotic and Autologous Fascia","status":"COMPLETED","sponsor":"Mohammad Sadegh Bagheri Baghdasht","startDate":"2016-01-01","conditions":"Tympanic Membrane Perforation","enrollment":30},{"nctId":"NCT02569866","phase":"PHASE2","title":"Antibiotics After Breast Reduction:Clinical Trial With Randomization","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2014-11","conditions":"Surgical Site Infection","enrollment":124},{"nctId":"NCT02911662","phase":"NA","title":"Treatment of Asymptomatic Bacteriuria in Pregnancy","status":"TERMINATED","sponsor":"Trinity Health Michigan","startDate":"2016-09","conditions":"Bacteriuria (Asymptomatic) in Pregnancy","enrollment":13},{"nctId":"NCT02145338","phase":"PHASE4","title":"Antibiotic Prophylaxis for Clean Intermittent Catheterisation","status":"COMPLETED","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","startDate":"2013-09","conditions":"Urinary Tract Infections, Recurrent","enrollment":404},{"nctId":"NCT02446496","phase":"PHASE4","title":"A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-31","conditions":"Infections, Urinary Tract","enrollment":24},{"nctId":"NCT01767584","phase":"PHASE1","title":"Bioequivalence Study of Cephalexin Tablets 1g","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-06","conditions":"Infections, Respiratory Tract","enrollment":26},{"nctId":"NCT01767532","phase":"PHASE1","title":"Bioequivalence Study of Cephalexin Suspension 125","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-30","conditions":"Infections, Respiratory Tract","enrollment":28},{"nctId":"NCT01767571","phase":"PHASE1","title":"Bioequivalence Study of Cephalexin Suspension 250","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-30","conditions":"Infections, Respiratory Tract","enrollment":28},{"nctId":"NCT03148444","phase":"PHASE4","title":"Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome","status":"UNKNOWN","sponsor":"Kaplan Medical Center","startDate":"2017-06-01","conditions":"Infection, Bacterial, Pacemaker Complication","enrollment":400},{"nctId":"NCT01899690","phase":"PHASE4","title":"Antibiotics and Tissue Expanders in Breast Reconstruction","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2016-06","conditions":"Complications; Breast Prosthesis, Infection or Inflammation","enrollment":""},{"nctId":"NCT01561703","phase":"NA","title":"Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2012-03","conditions":"Snoring, Strep Throat","enrollment":58},{"nctId":"NCT02490670","phase":"PHASE1","title":"A Study of Cephalexin Liquid in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-07","conditions":"Healthy","enrollment":28},{"nctId":"NCT00895089","phase":"PHASE4","title":"Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2009-05","conditions":"Liver Abscess","enrollment":24},{"nctId":"NCT02140281","phase":"PHASE1","title":"To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers","status":"COMPLETED","sponsor":"Ardelyx","startDate":"2014-05","conditions":"Healthy Volunteers","enrollment":71},{"nctId":"NCT02123446","phase":"PHASE1","title":"A Study of Cephalexin Capsules in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT02123472","phase":"PHASE1","title":"A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-05","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT02479867","phase":"PHASE1","title":"A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2014-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT01229553","phase":"NA","title":"Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients","status":"WITHDRAWN","sponsor":"State University of New York - Upstate Medical University","startDate":"2011-01","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT02123459","phase":"PHASE1","title":"A Study of Cephalexin Suspension in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-05","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT02100826","phase":"PHASE1","title":"A Study of Cephalexin in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT00187759","phase":"NA","title":"Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2004-11","conditions":"Soft Tissue Infections","enrollment":500},{"nctId":"NCT00300092","phase":"PHASE2","title":"Pediatric Fingertip Injuries:Are Antibiotics Required?","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2000-09","conditions":"Finger Injuries","enrollment":146},{"nctId":"NCT01073553","phase":"PHASE1","title":"Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-10","conditions":"Anti-Infective Agents","enrollment":26},{"nctId":"NCT00729937","phase":"PHASE2, PHASE3","title":"Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus \"STOP MRSA\"","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-04","conditions":"Staphylococcal Infection","enrollment":2265},{"nctId":"NCT01823523","phase":"NA","title":"Orthognathic Surgery and Postoperative Antibiotic Use","status":"UNKNOWN","sponsor":"Atlantic Center for Oral and Maxillofacial Surgery","startDate":"2013-06","conditions":"Dentofacial Deformity","enrollment":300},{"nctId":"NCT01400867","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12","conditions":"Infections, Pediatrics","enrollment":163},{"nctId":"NCT01155154","phase":"NA","title":"Antibiotic Prophylaxis for Simple Hand Lacerations","status":"TERMINATED","sponsor":"State University of New York - Downstate Medical Center","startDate":"2010-02","conditions":"Simple Hand Lacerations","enrollment":73},{"nctId":"NCT01613092","phase":"PHASE4","title":"Prevention of Arrhythmia Device Infection Trial (PADIT)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2011-05","conditions":"Arrhythmia","enrollment":241},{"nctId":"NCT01105208","phase":"PHASE1","title":"Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-03","conditions":"Anti-Infective Agents","enrollment":26}],"_emaApprovals":[],"_faersSignals":[{"count":2541,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":1764,"reaction":"ACUTE KIDNEY INJURY"},{"count":1740,"reaction":"RENAL FAILURE"},{"count":1621,"reaction":"DIARRHOEA"},{"count":1619,"reaction":"PAIN"},{"count":1484,"reaction":"FATIGUE"},{"count":1453,"reaction":"NAUSEA"},{"count":1373,"reaction":"DYSPNOEA"},{"count":1312,"reaction":"ANXIETY"},{"count":1303,"reaction":"RASH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"💊","route":"Oral","frequency":"Every 6 hours or every 12 hours","formulation":"capsule"},"crossReferences":{"chemblId":"CHEMBL1200366"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"Unknown–present","companyName":"Various","relationship":"Generic manufacturer"}],"publicationCount":3215,"therapeuticAreas":["Immunology"],"trialPhaseCounts":{"":3,"NA":11,"PHASE1":5,"PHASE2":6,"PHASE3":5,"PHASE4":19,"PHASE1, PHASE2":1},"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"CEPHALEXIN","genericName":"CEPHALEXIN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1971","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-02-24T00:00:00.000Z","mah":"CHARTWELL RX","brand_name_local":null,"application_number":"ANDA065152"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-08-17T00:00:00.000Z","mah":"LUPIN","brand_name_local":null,"application_number":"ANDA065234"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-11-16T00:00:00.000Z","mah":"AUROBINDO PHARMA","brand_name_local":null,"application_number":"ANDA065253"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-09-15T00:00:00.000Z","mah":"LUPIN","brand_name_local":null,"application_number":"ANDA065229"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-03-26T00:00:00.000Z","mah":"ALKEM LABS LTD","brand_name_local":null,"application_number":"ANDA210221"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T00:17:28.856449+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}